

Boston Scientific

Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program

PRNewswire-FirstCall
NATICK, Mass.
(NYSE:BSX)

NATICK, Mass., March 31 [/PRNewswire-FirstCall/](#) -- Boston Scientific Corporation (NYSE: BSX) today announced the sale of Boston Scientific Santa Rosa Corp., formerly known as TriVascular, Inc., to TV2 Holding Company, a privately held company based in Santa Rosa, California. Boston Scientific Santa Rosa Corp. holds equipment and intellectual property related to the TriVascular endovascular aortic repair (EVAR) program. Terms of the sale include \$30 million in cash paid at closing to Boston Scientific and a warrant allowing Boston Scientific to purchase a minority interest in TV2.

Boston Scientific acquired TriVascular, which was founded to develop EVAR devices and procedures for treating abdominal aortic aneurysms, in April 2005. Boston Scientific discontinued its EVAR program in 2006.

"The sale of this business is the latest example of Boston Scientific's commitment to divesting non-strategic assets," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "These divestitures -- together with our expense and head count reductions and business restructuring -- are helping realign our cost structure and simplify our operating model as we progress toward achieving our overall goals of restoring profitable growth, increasing shareholder value and strengthening Boston Scientific for the future."

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: <http://www.bostonscientific.com/>.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our divestiture of non-strategic assets, our restructuring initiatives, our operational strategy, our financial performance and our growth strategy. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; disposition of non-strategic assets, and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACTS: Paul Donovan
508-650-8541 (office)
508-667-5165 (mobile)
Media Relations
Boston Scientific Corporation

Larry Neumann
508-650-8696 (office)
Investor Relations
Boston Scientific Corporation

SOURCE: Boston Scientific Corporation

CONTACT: Media, Paul Donovan, +1-508-650-8541 (office), +1-508-667-5165 (mobile); Investors, Larry Neumann, +1-508-650-8696 (office, both of Boston Scientific Corporation

Web site: <http://www.bostonscientific.com/>

<https://news.bostonscientific.com/sale-endovascular-aortic-repair>